Open AccessOocyte and embryo cryopreservation before gonadotoxic treatments: Principles of safe ovarian stimulation, a systematic review
Author(s) -
Meghan C.H. Ozcan,
Victoria Snegovskikh,
G. David Adamson
Publication year - 2022
Publication title -
women's health (london. print)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.363
H-Index - 39
eISSN - 1745-5065
pISSN - 1745-5057
DOI - 10.1177/17455065221074886
Subject(s) - oocyte cryopreservation , fertility preservation , fertility , embryo cryopreservation , menstrual cycle , oocyte , medicine , gynecology , premature ovarian failure , ovarian tissue cryopreservation , randomized controlled trial , cryopreservation , biology , embryo , population , environmental health , hormone , microbiology and biotechnology
Objective: Review the safety of fertility preservation through ovarian stimulation with oocyte or embryo cryopreservation, including cycle and medication options.Evidence review: A systematic review of peer-reviewed sources revealed 2 applicable randomized control trials and 60 cohort studies as well as 20 additional expert opinions or reviews.Results: The capacity for future family building is important for the majority of reproductive age people, despite life-altering medical or oncologic diagnosis. Modern fertility preservation generates a high rate of oocyte yield while utilizing protocols that can be started at multiple points in the menstrual cycle and suppressing supra-physiologic levels of estrogen. Finally, more than one quarter of fertility preservation patients will return to later utilize fertility services.Conclusion: For most patients, fertility preservation can safely be pursued and completed within 2 weeks without affecting disease severity or long-term survival.